Glycine modulators in schizophrenia.
N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiology of schizophrenia. Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent negative and cognitive symptoms. Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clinical trials. Glycine levels in brain are regulated by GLYT1-type glycine transporters. Recently developed glycine transport inhibitors (GTI) have preclinical behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent negative and cognitive symptoms of schizophrenia.
Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg 10962, USA. Javitt@nid.rfmh.org
Daniel C
DC
Javitt
D000818:Animals; D005998:Glycine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018009:Receptors, Glycine / Q000819:agonists*; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism*
D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C435781:org 24598; D005998:Glycine